Posted: 5 December 2025
A new report has been released detailing the strong outcomes achieved through MTPConnect’s Clinical Translation Commercialisation Medtech (CTCM) Programme, highlighting the advances made by emerging Australian medtech companies supported through the initiative.
Speaking at MTPConnect’s Accelerator Showcase in Melbourne, where the report Driving Australian Medtech Innovation Success was launched, CEO Stuart Dignam said the programme has played a pivotal role in reducing risk for investors, accelerating clinical trials and driving growth across the sector. “Through this $19.75 million programme, $64 million has been injected into Australia’s medtech sector and there is more to come,” he said.
The CTCM Programme was established in 2021 with support from the Medical Research Future Fund and designed to help bring early-stage technologies to patients more quickly. The model provided integrated guidance, deep technical and commercial expertise, and targeted support to assist companies to run early clinical trials and build towards commercial readiness.
Key outcomes outlined in the report showed that 75 per cent of companies involved attracted additional investment, advancing their technologies toward market. The programme supported the progression of 36 new medical technologies, facilitated 16 collaborative research agreements, built 23 partnerships and helped drive 49 local manufacturing activities. One technology achieved US regulatory approval to enter the American market.
The Showcase event, opened by the Minister for Health, Ageing and Disability, the Hon Mark Butler MP, celebrated the achievements of homegrown innovators whose developments place patient needs at the centre of design. Across the programme, 247 end users contributed to co-design processes, with 51 clinicians and almost 400 patients participating in clinical trials in Australia and internationally.
Mr Dignam noted that the programme’s success demonstrates Australia’s capacity to nurture world-class science and transform it into scalable, investable medical technologies, reinforcing MTPConnect’s commitment to strengthening the national medtech ecosystem.
